Anne Sophie V. K.
- Country
- Norway
- Department
- Department of Haematology
Research Overview
- Phase II Evaluation of Azacitidine and Low-Dose Venetoclax in Acute Myeloid Leukemia with Multi-Omics and Ex Vivo Drug Screening Integration
- Evaluation of Revumenib Combined with Azacitidine and Venetoclax in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Patients Ineligible for Intensive Chemotherapy
- Evaluation of Ivosidenib and Azacitidine With or Without Venetoclax in IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Data & Insights
Has run more than one trial at 113 of 183 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating acute myeloid leukemia (AML) and related blood disorders, with particular focus on developing innovative therapeutic approaches for patients with varying disease stages.
- Advanced AML Treatment Protocols
- High-risk Myelodysplastic Syndrome Management
- Novel Combination Therapies
Expertise includes treatment strategies for both newly diagnosed and treatment-resistant cases.
Therapeutic Innovation
Demonstrates expertise in evaluating targeted therapeutic combinations, including the integration of established medications with newer treatment modalities for blood cancers.
- Venetoclax-based Combinations
- Alternative Treatment Approaches
- Patient-specific Treatment Optimization
Focuses on developing treatment options for patients unsuitable for standard chemotherapy protocols.
Clinical Assessment
Specializes in comprehensive evaluation of treatment efficacy and patient outcomes in hematologic conditions, with emphasis on monitoring therapeutic responses.
- Response Rate Assessment
- Performance Status Evaluation
- Safety and Tolerability Studies
Incorporates advanced assessment methods including survival analysis and response monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.